At ASH, drugmakers to showcase early data for three-pronged cancer therapies

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 05 Nov, 17:09 UTC

J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.